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Prognosis of invasive ductal carcinoma (IDC) strongly correlates with tumor grade as determined by Nottingham combined
histologic grade. While reporting grade as low grade/favorable (G1), intermediate grade/moderately favorable (G2), and high
grade/unfavorable(G3)isrecommendedbyAmericanJointCommitteeonCancer(AJCC)stagingsystem,existingTNM(Primary
Tumor/Regional Lymph Nodes/Distant Metastasis) classiﬁcation does not directly incorporate these data. For large tumors (T3,
T4), signiﬁcance of histologic grade may be clinically moot as those are nearly always candidates for adjuvant therapy. However,
for small (T1, T2) node-negative (N0) tumors, grade may be clinically relevant in inﬂuencing treatment decisions, but data on
outcomes are sparse and controversial. This retrospective study analyzes clinical outcome in patients with small N0 IDC on the
basis of tumor grade. Our results suggest that the grade does not impact clinical outcome in T1N0 tumors. In T2N0 tumors,
however, it might be prognostically signiﬁcant and relevant in inﬂuencing decisions regarding the need for additional adjuvant
therapy and optimal management.
1.Introduction
While the World Health Organization, College of American
Pathologist, and American Joint Commission on Cancer all
endorsereportinghistologictumorgradeforIDC,itdoesnot
directly factor into the current TNM staging system [1–3].
The Nottingham Combined Histologic Grade (NCHG), the
preferred grading system, stratiﬁes tumors into three grades
based on semiquantitative evaluation of tubule formation,
nuclear pleomorphism, and mitoses [4]. Histologic tumor
grade,asdeterminedbyNCHG,correlateswithprognosis[5]
and might represent a simple and inexpensive way to identify
low-risk patients who are highly curable by surgery alone or
arealsoin need ofadjuvanttherapy [6,7].Patientswithlarge
tumors are almost always candidates for adjuvant therapy, so
incorporating histologic grade in such cases may be clinically
irrelevant [8]. Also, tumor size often correlates with tumor
grade [9]. In this era of mammographic screening, however,
an increasing proportion of identiﬁed breast cancers are
small and node negative. Whether or not histologic grade
is an independent prognostic factor in small, node-negative
IDC is still an unresolved question [10]. The Breast Task
Force of the AJCC has noted that the data on this issue
are sparse and inconsistent, and as such, it refrained from
directly including the histologic tumor grade into the
TNM staging. While the existing data clearly diﬀerentiate
the prognosis of G1 and G3 tumors, the behavior of G2
tumors is ambiguous owing to methodologic diﬀerences
(followup times, grading systems, and measured outcomes).
We undertook a retrospective study to analyze the clinical2 Pathology Research International
Table 1: Tumor stage, grade, and clinical outcome.
T1a (n = 10) T1b (n = 23) T1c (n = 45) T2 (n = 33)
G1 G2 G3 G1 G2 G3 G1 G2 G3 G1 G2 G3
Alive without disease 1 4 3 5 10 5 8 20 15 1 15 11
Alive, status unknown — — 1 — 1 — — — — — — —
Alive with disease — 1 — — — — — — — — — 1
Deceased without disease — — — — 1 — — 1 1 — 1 1
Deceased, cause unknown — — — — — — — — — — — —
Deceased with disease — — — 1 — — — — — — — 3
T o t a l 1 5 4 61 2 5 82 11 6 11 61 6
G—tumor histologic grade.
Table 2: Clinical outcome by tumor grade in small (T1, T2) node-negative breast adenocarcinomas.
Tumor Size T1 (N = 76)
∗ T2 (N = 33)
Clinical Outcome∗∗ Clinical Outcome∗∗
Without Disease With Disease Without Disease With Disease
Tumor Grade N % N % P∗∗∗ N % N % P∗∗∗
G1-G2 50 66 2 3 17 52 0 0
G3 24 31 0 0 .46 12 36 4 12 .04
∗Excludes 2 alive, status unknown.
∗∗Clinical outcome includes patients living and deceased.
∗∗∗The p-value is for a one-tailed Fisher exact test.
outcomes in patients with small, node-negative cancers in an
attempt to contribute to this ongoing debate regarding the
prognostic signiﬁcance of histologic tumor grade.
2.Design
The ﬁles of the Department of Pathology, University of
Kentucky Medical Center were searched from January 1995
through July 2007 and yielded a total of 111 lumpec-
tomy/mastectomy specimens from patients with T1N0 or
T2N0 tumor status. The cases included 10 T1a, 23 T1b, 45
T1c, and 33 T2 tumors. The age of patients ranged from
31 to 83 years (mean, 55 years). The length of followup
ranged from 7 to 152 months (mean, 56 months), with
at least 60 months (5 years) and longer followup in 56%
of patients. Presence of coexistent ductal carcinoma in-
situ (DCIS), lymphovascular invasion (LVI), estrogen and
progesterone receptor (ER/PR), and HER-2/neu status by
immunohistochemistry was analyzed. Clinical followup data
with outcome through year 2008 were obtained from Tumor
Registry. The tumor size and histologic grade in conjunction
with clinical outcome was analyzed.
3. Results
The data for tumor size, histologic grade, and patient status
are summarized in Table 1. On the followup of patients
with T1 tumors, 71/78 (93%) were alive and 3 deceased
withoutdisease.Onlyonepatientdiedwithdisease(G1/stage
T1b), and another patient was alive with disease recur-
rence (G2/stage T1a). Two patients were alive with status
unknown. Of the patients with T2 tumors, 27/33 (82%)
were alive and two deceased without disease on followup.
Three died with disease (all ER negative, including one triple
negative), and one was alive with disease; all four (12%)
had G3 tumors (including two with LVI). All patients with
hormone receptor positive tumor status received Tamoxifen
or aromatase inhibitors. Of patients with T1 tumors, 24%
received chemotherapy, as did 67% of patients with T2
tumors (2 of 4 with recurrent/ progressive disease had
chemotherapy).
Of T1 tumors, 76% (59/78) showed DCIS versus 69%
(22/32) in T2 tumors. LVI was identiﬁed in 3% (1/33) of
T1a/T1b, 13% (6/45) of T1c, and 24% (8/33) of T2 tumors.
Positive ER and PR status was reported in 71% (55/78) and
64%(50/78)ofT1tumors,respectively,and63%(20/32)and
69% (22/32) of T2 tumors, respectively. All three deceased
patients with T2 tumors were tested ER negative. Two of
those three tumors also showed LVI. The patient with the
T1b tumor who died of disease had ER-positive tumor and
no LVI. HER-2/neu status was unknown in this case. Positive
HER-2/neu status was reported in 1/61 T1 tumors and 5/26
T2 tumors. Of three deceased cases, HER-2/neu status was
reported in only one and was negative. Both patients who are
alive with disease had positive ER and negative HER-2/neu
tumors, and no LVI.
The relationship between the tumor grade and clinical
outcome moderated by tumor size has been determined by
using the Fisher exact tests (Table 2).
The results of the Fisher exact tests suggest an interaction
eﬀect—with the relationship between tumor grade and
clinical outcome moderated by tumor size. That is, among
patients with T1 tumors (n = 76), clinical outcome didPathology Research International 3
not vary signiﬁcantly by tumor grade (P = .46). However,
among the T2 group (n = 33), the number of patients with
G3 tumors who were with disease (n = 4) was signiﬁcantly
greater than those with G1-G2 tumors (n = 0)(P = .04). The
strength of the relationships (ϕ)b e t w e e nt u m o rg r a d ea n d
clinical outcome for the T1 and T2 groups was.11 and.38,
respectively.
4. Discussion
Regardless of histologic grade, the overall prognosis for
small node-negative breast adenocarcinomas appears to be
very good. In the current study, the disease-free survival
for patients with T1N0 tumor status was 93% (71/76) and
for patients with T2N0 was 88% (29/33). This relatively
good prognosis is similar to that reported in prior studies
[5, 11, 12], and the diﬃculty of addressing the prognostic
signiﬁcance of histologic grade in these breast cancers is
highlighted. Namely, studies would need to be larger to
have the statistical power to detect a relationship between
histologic grade and clinical outcomes. Beyond sample size,
length of followup is also an important consideration as
recurrence may occur quite late [13–15].
While some studies have shown histologic grade to
be prognostically signiﬁcant in small, node-negative breast
carcinomas [5, 16, 17], other studies [18–20]d on o td e m o n -
strate this association. Lundin et al. suggest that omission of
histologic grading from clinical decision making may result
in considerable overuse of adjuvant therapies [21]. Based on
our data in this relatively small study, there is no evidence
that higher tumor grade impacts the clinical outcome in
T1N0 tumors. This tumor status was not associated with
higher rate of recurrence or disease persistence in our study.
In T2 tumors, however, our data suggest that histologic
tumor grade might be prognostically signiﬁcant and relevant
in inﬂuencing decisions regarding the need for additional
adjuvant therapy and optimal management of node-negative
breast carcinomas at this stage.
Currently, adjuvant hormonal and/or cytotoxic chem-
otherapies are recommended for most women with early-
stage invasive breast cancer. Treatment decisions are based
on axillary node status, age, tumor size, histologic tumor
type, tumor grade, hormone receptor status, and coexisting
medical conditions [22]. However, most patients with node-
negative disease who receive chemotherapy will not derive
beneﬁt because they would not go on to have a recurrence
even without such treatment, which also questions the
necessity of performing the Oncotype Dx testing in T1N0
tumors. New prognostic and predictive tests are needed to
better individualize therapy and conﬁne systemic treatment,
especially cytotoxic chemotherapy, to those patients who are
most likely to beneﬁt [23, 24]. Although based on a limited
material, our data may suggest more favorable prognosis for
patients with T1N0 regardless of tumor grade, as well as
low-grade T2N0 tumors, compared to those with high-grade
T2N0disease whomightbeneﬁtfromadditional chemother-
apy. Larger studies with considerable statistical power will be
needed to deﬁnitively demonstrate the impact of histologic
grade in these subsets of breast adenocarcinoma.
Several relatively recent studies indicate that the his-
tologic tumor grade appears to reﬂect speciﬁc molecular
predictiveindicatorssuchasproliferativemarkersandmulti-
geneexpressionarrays[25,26].Interestingly,thegradingwas
shown to correlate with other proposed prognostic factors
such as Recurrence Score (Oncotype Dx) and casting-type
microcalciﬁcations [23, 24, 27]. In the Kaiser population,
tumor size and tumor grade remained statistically signiﬁcant
associated with the risk of breast cancer death in most
multivariate models that also included the Recurrence Score
[23], whereas only tumor grade remained independently
associated with risk in the NCABP B-14 study [28]. The
Recurrence Score was able to identify a larger subset of
patients with low risk of breast cancer death than was
possible with either of the standard prognostic indicators
[23].
While currently the Breast Cancer Task Force has
elected not to include histologic grade as a stage-modifying
factor in the TNM system [8], it still does recommend
collection of tumor grade, using the standardized Not-
tingham combined histologic score with calibrated mitotic
counts, for inclusion in tumor registry database [1]. How
to merge histopathologic data with clinical, radiographic,
and molecular information into a therapeutic plan is an
evolving challenge. While many studies indicate the signif-
icance of Recurrence Score in predicting the magnitude of
chemotherapy beneﬁt, given the ﬁnancial constraints and
limited access to molecular testing within many health care
systems, studying the utility of histologic grade (along with
other parameters) continues to be relevant. For example,
based on the literature as well as our data, it might appear
that the Oncotype Dx testing (quoted price $4,075 per
test) is adding little or no additional prognostic value to
T1N0 and low-grade T2N0 tumors, which almost always
show favorable outcome with no recurrence. Ultimately,
determining if histologic grade will independently provide
clinically relevant information in these cases to serve as a
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